INmune Bio Inc

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

INmune Bio reports stable financials, eyes growth in diversified programs

INmune Bio's financials remain stable, with a strategic focus on advancing key programs and achieving upcoming milestones.
The company's strengths lie in efficient trial consolidation, diversification into solid tumors, and patient-centric treatment approaches.
Challenges include operational complexities, FDA holds, and the need for successful international site enrollments.
Opportunities for growth include new program launches, expansion into different therapeutic areas, and exploring combination therapies.

INmune Bio advances Alzheimer's and cancer treatments amidst financial strength

INmune Bio's Q1 2023 performance reflects a focus on advancing treatments for Alzheimer's, cancer, and other diseases, supported by a strong financial position.
While facing challenges such as FDA clinical hold and resource allocation, the company's commitment to innovation and diversification presents growth opportunities.
With upcoming milestones and a promising pipeline, INmune Bio is poised to make significant strides in addressing critical medical needs and expanding its therapeutic reach.

INmune Bio reports Q2 loss, progresses in Alzheimer's and solid tumors

INmune Bio's Q2 2023 earnings call highlighted progress in Alzheimer's and solid tumor treatments, with positive effects observed on gray matter microstructure.
The company's financials showed a net loss but with sufficient cash reserves for operations, while upcoming milestones signal growth potential.
Challenges include managing losses, regulatory progress, and market strategies, but opportunities lie in therapeutic advancements and diversification.

INmune Bio advances Alzheimer's and cancer trials amidst financial challenges

INmune Bio made progress in patient enrollment for Alzheimer's and prostate cancer trials, with a focus on regulatory milestones. Financially, the company reported a net loss but maintains a healthy cash position. Challenges include regulatory hurdles and competition, while opportunities exist in upcoming milestones and market expansion.

INmune Bio advances Alzheimer's and prostate cancer trials amid financial challenges

INmune Bio's Q4 2023 Earnings Call highlighted progress in Alzheimer's and prostate cancer trials, with positive regulatory developments. Financially, the company reported a net loss but maintains a healthy cash position. Analyst questions focused on trial specifics and market comparisons.

INmune Bio Inc advances Alzheimer's trials and secures funding for growth

INmune Bio Inc's Q2 2024 showcased progress in Alzheimer's trials, successful fundraising, and strategic milestones ahead
The company's leadership, financial stability, and upcoming trials position it well for growth and market recognition
While facing competitive challenges and operational complexities, INmune Bio Inc remains focused on innovation and market expansion

INmune Bio excels in clinical trials, secures funding for growth

INmune Bio's Q3 2024 earnings call highlighted strong clinical progress, financial growth, and a focus on data-driven decision-making for future success.
The company's emphasis on quality standards, innovative drug delivery, and promising trial results positions them well for upcoming milestones and market impact.
While facing inquiries and challenges, INmune Bio remains confident in its programs, signaling a resilient approach to addressing industry complexities and driving growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LA JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced  that CJ Barnum PhD, Head of Neurosciences will present data from the ongoing biomarker directed Phase Ib study of neuroinflammation in patients with Alzheimer’s disease.  The talk entitled, Phase 1b Study in AD Patients with Neuroinflammation​, will be given today at 11:20AM ET as part of this year’s virtual 21st International Conference on Alzheimer’s Drug Discovery meeting.  The trial continues to enroll patients and additional data on the Phase Ib study will be presented in the near future.

INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery

LA JOLLA, Calif., Sept.  23, 2020  (GLOBE NEWSWIRE) --    INmune Bio, Inc.    (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that the Company will be hosting a Key Opinion Leader (KOL) webinar on the topic of treatment resistant depression (TRD) at 1:00p.m. ET on Tuesday, September 29, 2020. The webinar will discuss the role of neuroinflammation in TRD and will feature presentations by two highly-regarded thought leaders in the field: Charles Raison, M.D., professor in the department of psychiatry at the University of Wisconsin at Madison, and John E. Schneider, Ph.D., chief executive officer and principal of Avalon Health Economics.

INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29

100 patient blinded, randomized, biomarker-directed Phase 2 study will use neuroimaging technology to study the complex biology of treatment resistant disease

INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression

LA JOLLA, Calif., Sept.  03, 2020  (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the United States Patent & Trademark Office (USPTO) has issued US Pat. No. 10,758,567 B2, titled “IN VIVO PRIMING OF NATURAL KILLER CELLS,” which covers a method for treating cancer using INKmune™, a natural killer (NK) cell priming technology. The patent expires in 2036.

INmune Bio, Inc. Announces Issuance of Patent from U.S.

LA JOLLA, Calif., Aug.  13, 2020  (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the European Patent Office (EPO) has granted EP Pat. No. 2,892,547, titled “A DOMINANT NEGATIVE TNF-ALPHA INHIBITOR FOR USE IN TREATING NEUROLOGICAL DISORDERS OF THE CNS,” which covers XPro1595 and its peripheral administration for treating Alzheimer’s Disease and other diseases of the CNS. The patent, which is set to expire in 2033, is owned by Xencor, Inc. and is licensed exclusively to INmune Bio.

European Patent Granted Covering INmune Bio’s XPro1595

INmune Bio Inc. (INMB) CEO RJ Tesi on Q2 2020 Results - Earnings Call Transcript

The company will host an earnings call: Today, August 5 at 4:30 PM ET The company will host an earnings call: Today, August 5 at 4:30 PM ET

INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update

LA JOLLA, Calif, July  31, 2020  (GLOBE NEWSWIRE) --  INmune Bio, Inc.  (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on August 5, 2020 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2020.

INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results

LA JOLLA, Calif, July  27, 2020  (GLOBE NEWSWIRE) --  INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease was featured on a Fox Business News segment.

INmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine Storm

LA JOLLA, Calif., July  20, 2020  (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, July 20th by INmune Bio, Inc. (NASDAQ: INMB) was incorrectly reported with below sentence:

Correction: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option

LA JOLLA, Calif., July  20, 2020  (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced the  closing of its previously announced underwritten public offering of an aggregate of 2,173,914 shares of its common stock at a public offering price of $10.00 per share and the exercise in full of the underwriters’ option to purchase an additional 326,086 shares of common stock. A total of 2,500,000 shares of common stock were issued in the offering, including the full exercise of the over-allotment option. 

INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option

LA JOLLA, Calif, July  16, 2020  (GLOBE NEWSWIRE) --    INmune Bio, Inc.   (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced today the pricing of its  underwritten public offering of an aggregate of 2,173,914 shares of its common stock at a public offering price of $10.00 per share.   In addition, INmune has granted the underwriters an over-allotment option, exercisable for 45 days from today to purchase up to an additional 326,086 shares of common stock at the public offering price, less the underwriting discounts and commissions.  The offering is expected to close on or about July 20, 2020, subject to customary closing conditions.

INmune Bio, Inc. Prices Public Offering of Common Stock

INmune Bio: Stronger Support From Alzheimer's Drug XPro1595

LA JOLLA, Calif., July  15, 2020  (GLOBE NEWSWIRE) --  INmune Bio, Inc.  (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. In addition, the Company intends to grant the underwriters an over-allotment option, exercisable for 45 days from the date of closing of the offering, to purchase up to an additional 15% of the shares of common stock sold in the public offering on the same terms and conditions.

INmune Bio, Inc. Announces Proposed Public Offering of Common Stock

Inmune Bio (INMB) stock is taking off on Tuesday after announcing positive Alzheimer's news for its leading drug candidate XPro1595.

Alzheimer’s News: Why INmune Bio (INMB) Stock Is Skyrocketing 125% Today

Inmune Bio stock skyrocketed to a record high Tuesday after the biotech company unveiled promising results for its Alzheimer's treatment. The drug targets inflammation in the brain.

Tiny Biotech Skyrockets To A Record High On Promising Alzheimer's News

Micro-cap biotech INmune Bio Inc (NASDAQ: INMB) is advancing strongly Tuesday following a positive clinical readout from the company.

INmune Surges Higher On Interim Alzheimer's Data

XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory

INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease

Study will be the first-in man trial for INKmune – a novel therapy to prime the patient’s own NK cells to attack their cancer

INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS

Review highlights the history, progress and potential of cells of the innate immune system that can be harnessed for treatment of cancer

Killers at the Crossroad – A Published Review of Innate Immune Cell Potential in Treatment of Cancers Published by Co-Founder and CSO of INmune Bio, Inc.

INmune Bio Inc. (INMB) CEO RJ Tesi on Q1 2020 Results - Earnings Call Transcript

The company will host an earnings call: Today, May 14 at 4:30 PM ET The company will host an earnings call: Today, May 14 at 4:30 PM ET

INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update

LA JOLLA, Calif., April  22, 2020  (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the United States Patent and Trademark Office (USPTO) has given formal notice of allowance in patent application serial no. 15/268,399, titled “IN VIVO PRIMING OF NATURAL KILLER CELLS,” which covers a method of treating cancer by administering a proprietary inactivated cellular material preparation and contacting a patient’s own natural killer cells within the body to induce an in vivo response, namely, the priming of NK cells for enhancing innate immunity and the NK cell ability to recognize and kill cancer cells within the patient.

INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells

Conference call at 4:15 PM ET with management to discuss the science and strategy of clinical trial to determine if  ﻿ the Company’s  DN-TNF platform could be used to treat catastrophic complications of COVID-19 – call-in information below

INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19

News for INmune Bio Inc Stock (INMB)